The Medical Establishment Doubles Down on Its Faulty Effort to Sell ‘Gender-Affirming Care’

Concerns about the efficacy of so-called gender-affirming care stem from the universally poor quality of studies that inform the topic. These worries could be addressed through a well-executed randomized control trial, conventionally the gold standard of medical research. A new study released this week is the first ever randomized control trial on the issue, but it was so poorly executed that it only obfuscates and misleads.

The study — “Early Access to Testosterone Therapy in Transgender and Gender-Diverse Adults Seeking Masculinization” — was published in the Journal of the American Medical Association (JAMA), a once-esteemed journal that has become so deeply politicized that it’s now a preeminent source of medical misinformation.